American Assets Inc. Takes Position in Lantheus Holdings, Inc. $LNTH

American Assets Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 17,000 shares of the medical equipment provider’s stock, valued at approximately $872,000. Lantheus comprises 0.3% of American Assets Inc.’s investment portfolio, making the stock its 11th largest holding.

Several other large investors have also recently modified their holdings of the business. Elevation Point Wealth Partners LLC purchased a new stake in shares of Lantheus during the 2nd quarter valued at approximately $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter valued at approximately $36,000. Hantz Financial Services Inc. raised its holdings in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares during the period. First Horizon Corp purchased a new stake in shares of Lantheus during the third quarter worth $26,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Mizuho raised their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Truist Financial boosted their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Stock Up 0.0%

Shares of Lantheus stock opened at $64.89 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29. The company’s 50 day moving average price is $65.59 and its 200-day moving average price is $59.64. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of 27.26 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. The firm had revenue of $384.01 million for the quarter, compared to analysts’ expectations of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.70 earnings per share. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.